Related references
Note: Only part of the references are listed.Novel agents in development for pediatric sarcomas
Dennis P. M. Hughes
CURRENT OPINION IN ONCOLOGY (2009)
Muramyl tripeptide (mifamurtide) for the treatment of osteosarcoma
Paul A. Meyers
EXPERT REVIEW OF ANTICANCER THERAPY (2009)
Novel bone cancer drugs: investigational agents and control paradigms for primary bone sarcomas (Ewing's sarcoma and osteosareoma)
Pete Anderson et al.
EXPERT OPINION ON INVESTIGATIONAL DRUGS (2008)
Liposomal muramyl tripeptide phosphatidyl ethanolamine: a safe and effective agent against osteosarcoma pulmonary metastases
Kanji Mori et al.
EXPERT REVIEW OF ANTICANCER THERAPY (2008)
Osteosarcoma: The same old drugs or more?
Stefan S. Bielack et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
Complexities in interpretation of osteosarcoma clinical trial results
Sally Hunsberger et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
Osteosarcoma: The addition of muramyl tripeptide to chemotherapy improves overall survival - A report from the Children's Oncology Group
Paul A. Meyers et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
Osteosarcoma (Osteogenic sarcoma)
Piero Picci
ORPHANET JOURNAL OF RARE DISEASES (2007)
Bone tumours in European children and adolescents, 1978-1997. Report from the Automated Childhood Cancer Information System Project
C. A. Stiller et al.
EUROPEAN JOURNAL OF CANCER (2006)
Liposomal muramyl tripeptide phosphatidylethanolamine:: Targeting and activating macrophages for adjuvant treatment of osteosarcoma
A Nardin et al.
CURRENT CANCER DRUG TARGETS (2006)
Signalling pathways and molecular interactions of NOD1 and NOD2
W Strober et al.
NATURE REVIEWS IMMUNOLOGY (2006)
Treatment of osteosarcoma at first recurrence after contemporary therapy - The Memorial Sloan-Kettering Cancer Center Experience
AJ Chou et al.
CANCER (2005)
Osteosarcoma: A randomized, prospective trial of the addition of ifosfamide and/or muramyl tripeptide to cisplatin, doxorubicin, and high-dose methotrexate
PA Meyers et al.
JOURNAL OF CLINICAL ONCOLOGY (2005)
Carrier-based strategies for targeting protein and peptide drugs to the lungs
SA Cryan
AAPS JOURNAL (2005)
Increased Fas expression reduces the metastatic potential of human osteosarcoma cells
EA Lafleur et al.
CLINICAL CANCER RESEARCH (2004)
Pattern of disease recurrence and prognostic factors in patients with osteosarcoma treated with contemporary chemotherapy
DS Hawkins et al.
CANCER (2003)
High dose ifosfamide in combination with high dose methotrexate, adriamycin and cisplatin in the neoadjuvant treatment of extremity osteosarcoma: Preliminary results of an Italian sarcoma group/Scandinavian sarcoma group pilot study
G Bacci et al.
JOURNAL OF CHEMOTHERAPY (2002)
Prognostic factors in high-grade osteosarcoma of the extremities or trunk:: An analysis of 1,702 patients treated on neoadjuvant cooperative osteosarcoma study group protocols
SS Bielack et al.
JOURNAL OF CLINICAL ONCOLOGY (2002)
Phase II/III trial of etoposide and high-dose ifosfamide in newly diagnosed metastatic osteosarcoma: A Pediatric Oncology Group trial
AM Goorin et al.
JOURNAL OF CLINICAL ONCOLOGY (2002)
Share Paper
